U.S. markets open in 4 hours 41 minutes
  • S&P Futures

    4,541.50
    +33.00 (+0.73%)
     
  • Dow Futures

    34,300.00
    +298.00 (+0.88%)
     
  • Nasdaq Futures

    15,944.00
    +74.25 (+0.47%)
     
  • Russell 2000 Futures

    2,175.40
    +29.10 (+1.36%)
     
  • Crude Oil

    67.05
    +1.48 (+2.26%)
     
  • Gold

    1,770.80
    -13.50 (-0.76%)
     
  • Silver

    22.33
    -0.00 (-0.02%)
     
  • EUR/USD

    1.1324
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    28.16
    +0.97 (+3.57%)
     
  • GBP/USD

    1.3311
    +0.0033 (+0.25%)
     
  • USD/JPY

    113.1960
    +0.4160 (+0.37%)
     
  • BTC-USD

    56,827.53
    -272.95 (-0.48%)
     
  • CMC Crypto 200

    1,448.50
    -20.58 (-1.40%)
     
  • FTSE 100

    7,123.10
    -45.58 (-0.64%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Emergent BioSolutions Inc (NYSE: EBS) will resume production of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.

  • The development comes after J&J last week slashed the 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce 1 billion shots.

  • Emergent Chief Executive Officer Robert Kramer said the resumption follows additional reviews and collaboration with the FDA and manufacturing partners.

  • The FDA has so far approved five batches from the Emergent facility since production there was paused, and J&J is working to clear additional doses for use, the drugmaker said last week.

  • "We will continue to work toward securing Emergency Use Authorization in the United States for drug substance manufactured at Emergent Bayview as quickly as possible," J&J said in an email.

  • The facility could make as many as 120 million doses a month at full capacity, but the finished doses might not be available until this fall, the Wall Street Journal reported.

  • Price Action: JNJ stock is down 0.40% at $171.49, and EBS shares are up 1.98% at $66.45 during the market session on the last check Thursday.

  • Image by torstensimon from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.